Health Highlights: April 22, 2019
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
FDA Approves First Device to Treat Children With ADHD
The first medical device to treat children with attention-deficit/hyperactivity disorder (ADHD) has been approved by the U.S. Food and Drug Administration.
The device delivers a low-level electrical pulse to areas of the brain linked with ADHD symptoms and is approved for treatment of children aged 7 to 12 who are not on medication for ADHD, CNN reported.
Treatment with NeuroSigma's Monarch external Trigeminal Nerve Stimulation System (eTNS) is by prescription and must be monitored by a caregiver.
"This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients through the use of mild nerve stimulation, a first of its kind," Carlos Pena, director of the FDA's Division of Neurological and Physical Medicine Devices, said in a statement.
The pocket-sized device is for use at home while a child is sleeping. It's connected by wire to a small patch placed on the child's forehead above the eyebrows, CNN reported.
In a clinical trial of 62 children, those who used the device had statistically significant improvements in their ADHD symptoms, compared to those who received a placebo, according to the FDA.
NeuroSigma's website says the device is not currently covered by insurance and could cost just over $1,000 for the starter kit, CNN reported.
The news stories provided in Health News and our Health-E News Newsletter are a service of the nationally syndicated HealthDay® news and information company. Stories refer to national trends and breaking health news, and are not necessarily indicative of or always supported by our facility and providers. This information is provided for informational and educational purposes only, and is not intended to be a substitute for medical advice, diagnosis, or treatment.